When it comes to health care law and advice, look no further than Dentons. Our lawyers are recognized leaders throughout Europe in their respective areas of expertise. We can assist your business with all decisions relating to your health care needs.

We understand that navigating the health care sector is challenging—combined with ever-changing regulatory restrictions and often limited budgets—and you need advice that is goal-oriented and cost-effective.

You can rely on our carefully selected teams of specialists who have many years of involvement in the health care industry. Dentons lawyers have a wealth of experience acting as legal advisors to health practitioners and businesses, including to organizations with business interests in the health and pharmaceuticals sector. We have an extensive client base in Europe and globally—we advise private and public hospital operators, health insurance companies and distributors of medical devices and consult physicians’ associations, pharmacy associations, financial investors and research institutions.

We offer you comprehensive and customized legal advice, in particular in the following areas:

• Hospital law, including hospital planning, hospital financing and statutory requirements for physicians
• Pharmaceutical law, law on medical devices and pharmacy law
• Regulatory requirements for health insurance funds
• Privacy laws in the health care sector
• Litigation and arbitration in the health care sector
• Regulatory law and compliance requirements for physicians
• Restructuring of corporations in the health care sector
• Acquisitions and sales of health care companies and related antitrust proceedings

Recognition

Dentons places in top 10 in major categories of PitchBook’s Global League Table Rankings

June 5, 2019

PitchBook’s Q1 2019 Global League Table Rankings have been released, and for the first quarter of 2019 reporting period we placed in the top 10 in all major categories. 

Insights

Life Sciences Legal Update - Q1 2024

March 27, 2024

Czech Republic: We bring you the first 2024 edition of the quarterly Life Science Legal Update, in which we regularly cover key legal aspects and innovations in the Pharmaceuticals and Life Sciences sectors. The first quarter of 2024 is full of news in the pharmaceutical, healthcare services and food sectors. For instance, there has been much discussion about limiting the availability of HHC substances to consumers; in addition, several implementing regulations for the amendment to the Medicines Act have come into force as well as a new pricing regulation under which health insurers will now be able to request a maximum price for a specific medicinal product as part of an exceptional reimbursement regime. The EU is about to negotiate the draft pharmaceutical package presented by the European Commission. Last but not least, the major amendment to the Significant Market Power Act which has been newly effected, and which largely affects buyer-supplier relationships in the supply of food, agricultural products and other related services.

Life Sciences Legal Update - Q1 2024 (Czech)

March 27, 2024

Czech Republic: We bring you the first 2024 edition of the quarterly Life Science Legal Update, in which we regularly cover key legal aspects and innovations in the Pharmaceuticals and Life Sciences sectors. The first quarter of 2024 is full of news in the pharmaceutical, healthcare services and food sectors. For instance, there has been much discussion about limiting the availability of HHC substances to consumers; in addition, several implementing regulations for the amendment to the Medicines Act have come into force as well as a new pricing regulation under which health insurers will now be able to request a maximum price for a specific medicinal product as part of an exceptional reimbursement regime. The EU is about to negotiate the draft pharmaceutical package presented by the European Commission. Last but not least, the major amendment to the Significant Market Power Act which has been newly effected, and which largely affects buyer-supplier relationships in the supply of food, agricultural products and other related services.

Dentons Prague Alert - Amendment to the Medicines Act

January 11, 2024

Czech Republic: On 29 December, the Amendment to the Medicines Act was published in the Collection of Laws, in volume 203 under number 456/2023 Coll. Barring one exception, the amendment already went into effect on 1 January 2024.

View all insights for Health Care in Europe

News and Events

Recent Press Releases

Dentons Paris advises Gilde Healthcare on its sale of RAD-x to a consortium of European investors

June 25, 2024

Dentons Paris has advised Gilde Healthcare on the sale of its majority stake in RAD-x to a consortium made up of Swiss Life Asset Managers and Vesper Infrastructure Partners. The consortium will support the growth ambitions of the pan-European medical imaging specialist RAD-x with a significant development plan aimed at extending its presence in Europe.

Dentons advises Sabadell Asabys and Thuja on Gradient Denervation Technologies €14 million Series A financing round

September 18, 2023

Dentons advises Sabadell Asabys and Thuja on Gradient Denervation Technologies €14 million Series A financing round. Sabadell Asabys led this round through its new fund Sadabell Asabys II, accompanied by Thuja capital and founding investor Sofinnova Partners.

Dentons advises Impress on largest ever Series A financing in Spain and Southern Europe

May 31, 2021

Dentons advised Impress, a Barcelona-based, digitally-led orthodontic chain, on its Series A financing, in which the company raised US$50 million to expand its operations across the continent. The investors included CareCapital, one of the world’s largest dental-focussed private equity firms, Nickleby Capital and UNIQA Ventures. Existing investors, TA Ventures and Bynd VC, also participated in the round. This marks the largest ever Series A round in Spain and Southern Europe.

View all press releases for Health Care in Europe